VECTOR in Russia Developed Coronavirus Test To Test Almost 100 People At The Same Time

  • Vector is also working on the coronavirus vaccine.
  • The test uses non live virus, hence it is not dangerous.
  • The test can be performed in any lab and provides results for 93 people at the same time.

The numbers continue to increase in US and it is predicted that in many US states the peak of the coronavirus will not hit fully until May. Hence, it could mean the shut down of all non essential businesses can continue into May. In Canada, it seems the closures will last until at least June 30th. However, the situation is being accessed daily.

There is not even one established and approved protocol for treating Coronavirus. There is reported use of anti-malaria drugs and combinations to treat the infected cases. One reported treatment options is using plasma from people who recovered from coronavirus as it contains necessary antibodies to help others.

VECTOR Center in Siberia.

There is a race to create a vaccine against COVID-19. US Biotech company Moderna  has entered Phase 2 of vaccine trials, which entails testing it on humans. Hopefully, the results would allow the vaccine to enter the market. Therefore, it could possibly stop this pandemic. According to research, there are 3 types of Coronavirus variations around the world.

On April 13th, Russia 1 channel announced a new coronavirus test, which allows the simultaneous testing 93 patients. The test is developed by the Vector Institute, a State Research Center of Virology and Biotechnology in Koltsovo, Novosibirsk Oblast, Russia.

It has research facilities and capabilities for all levels of Biological Hazard, CDC Levels 1–4.

A biosafety level (BSL), or Pathogen/Protection level, is a set of biocontainment precautions required to isolate dangerous biological agents in an enclosed laboratory facility. The levels of containment range from the lowest biosafety level 1 (BSL-1) to the highest at level 4 (BSL-4). In the United States, the Centers for Disease Control and Prevention (CDC) have specified these levels. In the European Union, the same biosafety levels are defined in a directive. In Canada the four levels are known as Containment Levels. Facilities with these designations are also sometimes given as P1 through P4 (for Pathogen or Protection level), as in the term P3 laboratory.

CDC Biosafety Levels.

The test works by using inactivated virus. It does not pose a risk since the virus is not live and it allows analysis of the 93 people simultaneously. The US and Canada and many other nations around the world face a big challenge of testing large groups of people. It is imperative to minimize risk by testing and determining positive coronavirus tests to allow better treatment results and recovery. Testing also helps to minimize the spread of the virus as much as possible besides the social distancing approach.

The test system can be used in a standard serological laboratory in almost any medical organization according to a Vector representative. Additionally, the blood of a person who has been ill with COVID-19 can be saturated with antibodies that neutralize the virus.

The CEO of Vector believes that it is possible to cope with the pandemic only through the formation of collective immunity. Vector is also testing a vaccine against the coronavirus. It is largely believed in the medical community the way to curb this pandemic on the global scale is successful vaccination.

Hopefully, the mass tests can become available around the world and help at present to fight this pandemic. It is highly likely the vaccine will be available by next year.

Only $1/click

Submit Your Ad Here

Christina Kitova

I spent most of my professional life in finance, insurance risk management litigation.

Leave a Reply